



# Erik Eijrond

Chief Operation Officer  
RegMed XB, the Netherlands





Regenerative medicine crossing borders - translating  
groundbreaking technologies into commercial companies and  
products



# RegMed XB Pilot factory for Regenerative Medicine

Building a new industry for regenerative medicine solutions for patients





RegMed XB is a public-private partnership in the Netherlands and Belgium (Flanders) dedicated to bringing **regenerative medicine solutions to patients** and creating a **new industrial sector** in the participating regions



(Provincial)  
Governments

### Health foundations



### SME & Industry



### Institutes

#### The Netherlands:



#### Flanders:






## Facts & Figures

- Public-private partnership
  - 5 research institutes in the Netherlands and Belgium
  - regional governmental bodies
  - >20 companies
  - 5 health foundations
- 500 scientists
- 4 Moonshots: Kidney, Heart, Osteoarthritis, Diabetes
- Started in 2016






# The RegMed XB translational platform






# Four Moonshots





# The RegMed XB translational platform






# What is the challenge and what is needed?

- Currently no industrial-scale manufacturing platform available → no scaling possible
- Goal: developing an (European) **industrial-scale manufacturing platform** for organoid based tissue-engineered implants and organs
  - cost-effective production
  - maximize patient access
  - commercially viable products





# RegMed XB develops a national Regenerative Medicine Pilot Factory



# Pilotfabriek voor regeneratieve geneeskunde van RegMed XB


*Uitgebreid plan voor het Groeifondsvoorstel  
Life Sciences & Health ecosysteem*

25-09-2020



## NATIONAL PILOT FACTORY FOR REGENERATIVE MEDICINE

HEADING TOWARDS:



interregional health cluster



# Pilotfactory for RG - RegMed XB (25/09/20)

- All pilot lines develop and supply independent products and services as well as products and services to each other
- The pilot lines work closely together and share knowledge and expertise, so that this new Dutch pilot production ecosystem can not only offer a complete proposition but are more than the sum of its parts.
- By exchanging experiences and people, developing standards together ... accelerate the upscaling of new production technology and processes even more

The pilot lines of the RG pilot plant thus add up to a rock-solid proposition that covers the entire chain from the development and pilot production of biomaterials to stem cells, micro- and macro-tissues, and organs for personalized, small-scale and indiscriminate application."



NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

NIEUWS  
POORT

 nieuwsport

## Persconferentie Nationaal Groeifonds

Met minister Adriaans en commissievoorzitter Dijksebloem

14 APRIL 2022



# Funding strategy

- Investment of 56 mio EUR secured by Dutch National Growth Fund for Pilot Factory
- Total funding adds up to 216 mio EUR (till 2028)
- Applications for European grants in near future (i.e. i3 grant)



# Responsibilities RegMed XB (26/11/21)

- Achieving cooperation and coordination between the pilot lines within the Netherlands and with Flanders
- Developing and marketing joint business proposition (valorization)
- Achieving the KPIs of pilot factory
- Integration pilot plant into the entire ecosystem of RegMed XB
- Monitoring, evaluating and reporting on joint and individual progress



# Planning

1. Physical infrastructure
2. Open-for-business
3. Scaling up the pilot lines



# What has already been achieved (Phase 1)?

- NecstGen: 4,000 m2, completion Q2 2022
- LUMC: Parallel to NecstGen, first customers Q4 2022
- UMC Utrecht: Equipment, start organization, building plans
- SBMC: Start organization and community, equipment, location
- ReGEN: Start organization, equipment, location



# Seeking for specific partnerships

1. Technologies related to upscaling of highly functional organoids for applications related to the moonshots (kidney, cartilage/ bone, Langerhans islets/ beta cells, myocardium), with preference for suspension culture systems
2. Technologies related to in-process real time monitoring systems of organoid based bioprocesses including bio-sensing and non-invasive imaging systems
3. Technologies related to human size tissue assembly using organoids as building blocks including 3D Bioprinting
4. Expertise/ experience in GMP transition of these bioprocesses
5. Translational/ clinical platforms in the application related to the moonshots

# NATIONAL PILOT FACTORY FOR REGENERATIVE MEDICINE

HEADING TOWARDS:



regenerative  
patient therapies




affordable  
healthcare



industrial activity/  
employment opportunities



R&D



picture: apm - zygote.be

Diabetes  
Fonds

don  
Stichting

Hartstichting

NIERSTICHTING

ReumaNederland

Central Government · Provinces · industrial partners · research organisations



REGMEDXB

Erik Eijrond

[e.eijrond@regmedxb.com](mailto:e.eijrond@regmedxb.com)

Website: [www.regmedxb.nl](http://www.regmedxb.nl)